Bedside Estimation of Risk From Percutaneous Coronary Intervention: The New Mayo Clinic Risk Scores

Singh, Mandeep; Rihal, Charanjit S.; Lennon, Ryan J.; Spertus, John; Rumsfeld, John S.; Holmes Jr, David R.
June 2007
Mayo Clinic Proceedings;Jun2007, Vol. 82 Issue 6, p701
Academic Journal
OBJECTIVE: To derive risk models for percutaneous coronary intervention (PCI) outcomes from clinical and laboratory variables available before the procedure so they can be used for preprocedure risk stratification. PATIENTS AND METHODS: Using the Mayo Clinic registry, we analyzed 9035 PCls on 7640 unique patients from January 1, 2000, through April 30, 2005. We included only the first PCI per patient (n=7457). Logistic regression was used to model the calculated risk score and major procedural complications. Separate risk models were made for mortality and major adverse cardiovascular events (MACE) derived solely from baseline and laboratory characteristics. Final risk scores for procedural death, defined as any death during the index hospitalization, and MACE contained the same 7 variables (age, myocardial infarction ≤24 hours, preprocedural shock, serum creatinine level, left ventricular ejection fraction, congestive heart failure, and peripheral artery disease). RESULTS: Models had adequate goodness of fit, and areas under the receiver operating characteristic curve were 0.74 and 0.89 for MACE and procedural death, respectively, indicating excellent overall discrimination. The model was robust across many subgroups, including those undergoing elective PCI, those having diabetes mellitus, and elderly patients. Bootstrap analysis indicated that the model was not overfit to the available data set. CONCLUSIONS: Before coronary angiography is performed, a risk-scoring system based on 7 variables can be used conveniently to predict cardiovascular complications after PCI. This model may be useful for providing patients with individualized, evidence-based estimates of procedural risk as part of the informed consent process.


Related Articles

  • Stem-Cell Transplantation in Myocardial Infarction: A Status Report. Lee, Michael S.; Makkar, Raj R. // Annals of Internal Medicine;5/4/2004, Vol. 140 Issue 9, p729 

    Myocardial infarction is the leading cause of congestive heart failure and death in the industrialized world. Current therapy is limited in preventing the progression of ventricular remodeling and congestive heart failure. Recent interest has focused on stem cells, which are undifferentiated and...

  • Moving Troponin Testing into the 21st Century: Will Greater Sensitivity Be Met with Greater Sensibility? Rosenbaum, Lisa S.; Januzzi, James L. // Cardiovascular & Haematological Disorders - Drug Targets;Jun2008, Vol. 8 Issue 2, p118 

    With its superior sensitivity and specificity, cardiac troponin has gradually replaced other cardiac enzymes, and is now the biomarker of choice in making the critical diagnosis of an acute coronary syndrome (ACS). The early stratification of risk from unstable angina to non-ST segment elevation...

  • From early to late ventricular remodeling after myocardial infarction: the role of echocardiographic assessment in surgical decisions. Cerin, Gheorghe; Florescu, Maria; Benea, Diana; Diena, Marco; Vinereanu, Dragos; Cinteza, Mircea // Maedica - a Journal of Clinical Medicine;2008, Vol. 3 Issue 2, p107 

    Left ventricular (LV) remodeling following a myocardial infarction (MI) is a pathologically process of change in size, shape and volumes, wall thickness and function of the heart. Remodeling changes begin in the acute period of MI and tend to continue long after that, leading to LV dysfunction...

  • Combining white blood cell count and thrombosis for predicting in-hospital outcomes after acute myocardial infraction. Rohani, Atooshe; Akbari, Vahid; Moradian, Karim; Malekzade, Janmohammad // Journal of Emergencies, Trauma & Shock;Jul2011, Vol. 4 Issue 3, p351 

    Introduction: Admission white blood cell (WBC) count and thrombosis in myocardial infarction (TIMI) risk score have been associated with adverse outcomes after acute myocardial infarction (AMI). This study investigated the joint effect of WBC count and TIMI risk score on predicting in-hospital...

  • The Association Between Clinical Pathways and Hospital Length of Stay: A Case Study. Keon-Hyung Lee; Anderson, Yvonne // Journal of Medical Systems;Feb2007, Vol. 31 Issue 1, p79 

    Clinical pathways are the treatment protocol in order to reduce or eliminate variation of care by specifying to nursing and medical staff. The effectiveness of the clinical pathways to accomplish this goal, however, is in question. With the implementation of the clinical pathways in 2001, this...

  • Complete Heart Block Complicating Acute Myocardial Infarction. Gupta, M. C.; Singh, M. M.; Wahal, P. K.; Mehrotra, M. P.; Gupta, S. K. // Angiology;Oct1978, Vol. 29 Issue 10, p749 

    Complete heart block (CHB) developed in 10.3% of patients with acute myocardial infarction (MI). It was more frequent among patients with inferior myocardial infarction compared to anterior myocardial infarction, but the mortality was significantly high among patients with anterior MI who...

  • Congestive heart failure: What can we offer our patients? Kostuk, William J. // CMAJ: Canadian Medical Association Journal;10/16/2001, Vol. 165 Issue 8, p1053 

    Focuses on medical care for patients with congestive heart failure. Steps to ensure proper management of patients with heart failure; Risk factors; Discussion of heart failure outpatient treatment programs.

  • Importance of chronic obstructive pulmonary disease for prognosis and diagnosis of congestive heart failure in patients with acute myocardial infarction. Kjøller, Erik; Køber, Lars; Iversen, Kasper; Torp-Pedersen, Christian; Trace Study Group, on behalf of the // European Journal of Heart Failure;Jan2004, Vol. 6 Issue 1, p71 

    Aims: To evaluate the importance of chronic obstructive pulmonary disease for prognosis and diagnosis of congestive heart failure in patients with acute myocardial infarction. Methods and results: Prospective registration of 6669 consecutive patients admitted with infarction and screened for a...

  • Antiplatelet therapy mitigates cardiac remodeling and dysfunction in congestive heart failure due to myocardial infarction. Sanganalmath, Santosh K.; Barta, Judit; Takeda, Nobuakira; Kumamoto, Hideo; Dhalla, Naranjan S. // Canadian Journal of Physiology & Pharmacology;Apr2008, Vol. 86 Issue 4, p180 

    Antiplatelet agents such as sarpogrelate (SAR), a 5-hydroxytryptamine antagonist, and cilostazol (CIL), a phosphodiesterase-III inhibitor, are used in the management of peripheral vascular disease. In this study, we tested the hypothesis that both SAR and CIL prevent cardiac remodeling and...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics